RYZUMVI (Phentolamine Mesylate) Patent Expiration, LOE Window & CMS Spending

RYZUMVI (Phentolamine Mesylate) by Famygen Life Sciences: FDA Orange Book core substance LOE 2034-01-31 (last listed 2039-10-25), 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorFamygen Life Sciences
FDA Application & PathwayN217064 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-01-31
Last Listed Patent or Exclusivity Date2039-10-25
Orange Book Patents (*PED Extensions)13 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel